Treatment and prophylaxis of sepsis and septic shock
A method and composition for the prophylaxis or treatment of humans or animals for septic shock and sepsis using a mixture of sophorolipids.
1. A composition for treatment of sepsis and septic shock in a human or animal comprising a mixture of sophorolipids and a pharmaceutically acceptable carrier, wherein:
the mixture of sophorolipids comprises Ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, and
the pharmaceutically acceptable carrier is selected from the group consisting of physiologically compatible buffers, physiological saline, a mixture consisting of saline and glucose, and heparinized sodium-citrate-citric acid-dextrose solution.
2. The composition as claimed in claim 1 , wherein the mixture of sophorolipids comprises 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate.
3. The composition as claimed in claim 1 , wherein the mixture of sophorolipids comprises Hexyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate.
4. The composition as claimed in claim 1 , wherein the composition is a pharmaceutically acceptable salt.
5. A composition for treatment of sepsis and septic shock in a human or animal comprising a mixture of sophorolipids, wherein the mixture of sophorolipids comprises Hexyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate.
6. The composition as claimed in claim 5 , wherein the mixture of sophorolipids is mixed with a pharmaceutically acceptable carrier.
7. The composition as claimed in claim 6 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of physiologically compatible buffers, physiological saline, a mixture consisting of saline and glucose, and heparinized sodium-citrate-citric acid-dextrose solution.
8. The composition as claimed in claim 5 , wherein the composition is a pharmaceutically acceptable salt.
9. A composition for treatment of sepsis and septic shock in a human or animal comprising a mixture of sophorolipids and a pharmaceutically acceptable carrier, wherein:
the mixture of sophorolipids comprises at least two sophorolipids selected from the group consisting of 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate, Ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, and Hexyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate;
the pharmaceutically acceptable carrier is selected from the group consisting of physiologically compatible buffers, physiological saline, a mixture consisting of saline and glucose, and heparinized sodium-citrate-citric acid-dextrose solution; and
the composition is a pharmaceutically acceptable salt.